Cargando…
SGOL2 promotes prostate cancer progression by inhibiting RAB1A ubiquitination
Prostate cancer is the most prevalent genitourinary malignant cancer in men worldwide. Patients with prostate cancer who progress to castration-resistant prostate cancer (CRPC) or metastatic CRPC have significantly poorer survival. Advanced prostate cancer is a clinical challenge due to the lack of...
Autores principales: | Lv, Tingting, He, Dongwei, Zhang, Xiaokuan, Guo, Xiaojin, Li, Zijie, Zhang, Aili, Fan, Bo, Wang, Zhiyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831743/ https://www.ncbi.nlm.nih.gov/pubmed/36566018 http://dx.doi.org/10.18632/aging.204443 |
Ejemplares similares
-
SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma
por: Hu, Qingqing, et al.
Publicado: (2022) -
SGOL1-AS1 enhances cell survival in acute myeloid leukemia by maintaining pro-inflammatory signaling
por: Selkirk, Ewan, et al.
Publicado: (2022) -
SGOL1 variant B induces abnormal mitosis and resistance to taxane in non-small cell lung cancers
por: Matsuura, Shun, et al.
Publicado: (2013) -
Sgol2 provides a regulatory platform that coordinates essential cell cycle processes during meiosis I in oocytes
por: Rattani, Ahmed, et al.
Publicado: (2013) -
Identification and validation of a potential key gene SGOL1 for poor prognosis in hepatocellular carcinoma based on a bioinformatics approach
por: Fei, Xiaobin, et al.
Publicado: (2022)